EHA 2021 Conference Review

In this review:

R-CHOP vs R-EPOCH in double or triple hit DLBCL
Axicabtagene ciloleucel in R/R follicular lymphoma
Zanubrutinib vs ibrutinib in R/R CLL/SLL
Brentuximab vedotin + chemo for Hodgkin lymphoma
DRd vs Rd in transplant ineligible newly diagnosed MM
Newly diagnosed AL amyloidosis treated with daratumumab + VCd
HMA, venetoclax + FLT3 inhibitor vs HMA + FLT3 inhibitor
RUNX1 mutations in newly diagnosed AML
MATRIX + ASCT in primary CNS lymphoma
Tisagenlecleucel in R/R follicular lymphoma

Please login below to download this issue (PDF)